Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

In a randomized, controlled trial, a ctDNA-guided approach to the postsurgical treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-06, Vol.386 (24), p.2261-2272
Hauptverfasser:	Tie, Jeanne, Cohen, Joshua D., Lahouel, Kamel, Lo, Serigne N., Wang, Yuxuan, Kosmider, Suzanne, Wong, Rachel, Shapiro, Jeremy, Lee, Margaret, Harris, Sam, Khattak, Adnan, Burge, Matthew, Harris, Marion, Lynam, James, Nott, Louise, Day, Fiona, Hayes, Theresa, McLachlan, Sue-Anne, Lee, Belinda, Ptak, Janine, Silliman, Natalie, Dobbyn, Lisa, Popoli, Maria, Hruban, Ralph, Lennon, Anne Marie, Papadopoulos, Nicholas, Kinzler, Kenneth W., Vogelstein, Bert, Tomasetti, Cristian, Gibbs, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Adjuvants Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Australia Biomarkers Cancer therapies Chemotherapy Chemotherapy, Adjuvant - methods Circulating Tumor DNA - analysis Circulating Tumor DNA - blood Clinical trials Colon cancer Colonic Neoplasms - blood Colonic Neoplasms - mortality Colonic Neoplasms - pathology Colonic Neoplasms - therapy Colorectal cancer Deoxyribonucleic acid Disease management Disease-Free Survival DNA Enrollments Fluorouracil - therapeutic use Gastroenterology Gastrointestinal Tract Cancer Hematology Humans Medical research Neoplasm Recurrence, Local - prevention & control Neoplasm Staging Oncology Oxaliplatin Oxaliplatin - therapeutic use Patients Statistical analysis Surgery Surveillance Survival Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized, controlled trial, a ctDNA-guided approach to the postsurgical treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2200075